(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
Hiscock, who took over as CFO in 2020, purchased the shares on Wednesday at an average price of 3,330.0p each, for a total value of...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE